KR102507657B1 - 약물 및 기타 물질 전달용 경구 조성물 - Google Patents

약물 및 기타 물질 전달용 경구 조성물 Download PDF

Info

Publication number
KR102507657B1
KR102507657B1 KR1020227016492A KR20227016492A KR102507657B1 KR 102507657 B1 KR102507657 B1 KR 102507657B1 KR 1020227016492 A KR1020227016492 A KR 1020227016492A KR 20227016492 A KR20227016492 A KR 20227016492A KR 102507657 B1 KR102507657 B1 KR 102507657B1
Authority
KR
South Korea
Prior art keywords
composition
general formula
formula
agent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227016492A
Other languages
English (en)
Korean (ko)
Other versions
KR20220070551A (ko
Inventor
월터 쇼
스티븐 더블유. 버지스
성룽 리
Original Assignee
아반티 폴라 리피즈, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아반티 폴라 리피즈, 엘엘씨 filed Critical 아반티 폴라 리피즈, 엘엘씨
Publication of KR20220070551A publication Critical patent/KR20220070551A/ko
Application granted granted Critical
Publication of KR102507657B1 publication Critical patent/KR102507657B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227016492A 2014-08-09 2015-08-10 약물 및 기타 물질 전달용 경구 조성물 Active KR102507657B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462035393P 2014-08-09 2014-08-09
US62/035,393 2014-08-09
KR1020177006233A KR20170033442A (ko) 2014-08-09 2015-08-10 약물 및 기타 물질 전달용 경구 조성물
PCT/US2015/044501 WO2016025401A1 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006233A Division KR20170033442A (ko) 2014-08-09 2015-08-10 약물 및 기타 물질 전달용 경구 조성물

Publications (2)

Publication Number Publication Date
KR20220070551A KR20220070551A (ko) 2022-05-31
KR102507657B1 true KR102507657B1 (ko) 2023-03-08

Family

ID=55304531

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227016492A Active KR102507657B1 (ko) 2014-08-09 2015-08-10 약물 및 기타 물질 전달용 경구 조성물
KR1020177006233A Ceased KR20170033442A (ko) 2014-08-09 2015-08-10 약물 및 기타 물질 전달용 경구 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177006233A Ceased KR20170033442A (ko) 2014-08-09 2015-08-10 약물 및 기타 물질 전달용 경구 조성물

Country Status (11)

Country Link
US (3) US9872908B2 (enExample)
EP (1) EP3177279B1 (enExample)
JP (1) JP6759203B2 (enExample)
KR (2) KR102507657B1 (enExample)
CN (1) CN107072967B (enExample)
AU (1) AU2015301952B2 (enExample)
CA (1) CA2956960C (enExample)
DK (1) DK3177279T3 (enExample)
ES (1) ES3033965T3 (enExample)
IL (1) IL250394B (enExample)
WO (1) WO2016025401A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015301952B2 (en) * 2014-08-09 2020-12-03 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514755A1 (fr) 1981-10-21 1983-04-22 Rhone Poulenc Chim Base Procede de preparation de l'anhydride acetique
ZA831053B (en) * 1982-02-17 1985-03-27 Ciba Geigy Ag Lipids in aqueous phase
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
JPH01274830A (ja) * 1988-04-28 1989-11-02 Asahi Denka Kogyo Kk 安全で且つ高度な界面活性を有する脂質組成物
JPH03127731A (ja) * 1989-10-12 1991-05-30 Yakult Honsha Co Ltd ビタミンｅの可溶化方法およびビタミンｅ製剤
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
EP2062574B1 (en) * 2006-09-08 2015-03-25 Kaneka Corporation Composition comprising reduced coenzyme q10 and lysolecithin
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
AU2015301952B2 (en) * 2014-08-09 2020-12-03 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
일본 공개특허공보 특개2014-516969 (2014.07.17.)*

Also Published As

Publication number Publication date
KR20220070551A (ko) 2022-05-31
IL250394A0 (en) 2017-03-30
IL250394B (en) 2021-05-31
KR20170033442A (ko) 2017-03-24
AU2015301952B2 (en) 2020-12-03
CA2956960C (en) 2023-10-24
EP3177279B1 (en) 2025-06-04
CN107072967B (zh) 2021-01-12
WO2016025401A1 (en) 2016-02-18
US9872908B2 (en) 2018-01-23
CN107072967A (zh) 2017-08-18
US11510985B2 (en) 2022-11-29
DK3177279T3 (da) 2025-08-18
AU2015301952A1 (en) 2017-02-16
EP3177279A1 (en) 2017-06-14
ES3033965T3 (en) 2025-08-11
JP6759203B2 (ja) 2020-09-23
CA2956960A1 (en) 2016-02-18
JP2017524036A (ja) 2017-08-24
US20180064813A1 (en) 2018-03-08
EP3177279A4 (en) 2018-04-18
US20200188518A1 (en) 2020-06-18
US20160166699A1 (en) 2016-06-16
US10463738B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
JP6666068B2 (ja) 外用組成物
US20190105268A1 (en) Viscoelastic Gel of Liraglutide Adapted for Once-Weekly or Once Bi-Weekly Administration
JP2013006790A (ja) Ｏ／ｗ型エマルジョン
JPWO2016104618A1 (ja) 医療用皮膚外用剤
KR102507657B1 (ko) 약물 및 기타 물질 전달용 경구 조성물
AU2011302885B2 (en) Non-aqueous oily injectable formulation exhibiting preservative efficacy
JP7149611B2 (ja) 薬物を保持した非水系組成物およびその製造方法
JP2017171643A (ja) 外用組成物
JP6735587B2 (ja) 外用組成物
JPWO2003099288A1 (ja) 医薬組成物
CN112521322B (zh) 氨基酸类化合物及组合物及其用于治疗牙周疾病的用途
JP2021004267A (ja) 医薬組成物
TWI624270B (zh) 藥物組合物
JP2013199458A (ja) カプセル製剤
WO2015150959A1 (en) Oral liquid pharmaceutical compositions comprising methyldopa or salts thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601